350 related articles for article (PubMed ID: 27148922)
1. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
[No Abstract] [Full Text] [Related]
2. Ixekizumab: First Global Approval.
Markham A
Drugs; 2016 May; 76(8):901-5. PubMed ID: 27098317
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.
Syed YY
Am J Clin Dermatol; 2017 Feb; 18(1):147-158. PubMed ID: 28138946
[TBL] [Abstract][Full Text] [Related]
4. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
5. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
Azevedo A; Torres T
Actas Dermosifiliogr; 2017 May; 108(4):305-314. PubMed ID: 27887675
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
[No Abstract] [Full Text] [Related]
10. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
11. Ixekizumab for treatment of psoriasis.
Dyring-Andersen B; Skov L; Zachariae C
Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
[TBL] [Abstract][Full Text] [Related]
12. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
Blauvelt A
Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
[TBL] [Abstract][Full Text] [Related]
13. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
Blegvad C; Skov L; Zachariae C
Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
[No Abstract] [Full Text] [Related]
15. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
[No Abstract] [Full Text] [Related]
18. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
[No Abstract] [Full Text] [Related]
19. IL-17 inhibitors for psoriasis.
Paek SY; Frieder J; Kivelevitch D; Menter MA
Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
[TBL] [Abstract][Full Text] [Related]
20. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
